Acute Kidney Injury, Arterial Hypertension, Cardio Vascular Disease, Chronic Liver Disease, Diabetes Mellitus, Hypercholesterolemia, Obesity
Conditions
Keywords
Biomarker, Intra Abdominal Surgery, AKI
Brief summary
To validate the use of \[TIMP-2\]●\[IGFBP-7\] to predict AKI in patients undergoing major intra abdominal surgery.
Detailed description
A prospective pilot single center study to investigate the potential of \[TIMP-2\].\[IGFBP-7\] to predict AKI (Acute Kidney Injury) in patients undergoing major abdominal surgery. The investigators will measure the biomarker once preoperatively and 4-times postoperatively starting at arrival on PACU (post anesthesia care unit).The primary endpoint of this study is the development of AKI stage 2 or 3 within the first 72 postoperative hours.
Interventions
DEVICENephro Check Test
Urine sample
OTHERserum creatinine measurement
Blood sample
Sponsors
Universitair Ziekenhuis Brussel
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥ 18 years * High risk patients: General Surgery AKI Risk Index Class III, IV or V * Major abdominal surgery
Exclusion criteria
* Ongoing acute kidney injury Stage 2/3 * History of kidney transplant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants diagnosed with AKI stage 2 or 3 using the updated rifle KDIGO guidelines | 72 Hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants who need renal replacement therapy | 30 Days | the need renal replacement therapy wil be evaluated by the nephrologist (acid base disturbances, hypervolemia,...) |
Other
| Measure | Time frame |
|---|---|
| 30-day mortality | 30 days |
| persistence of renal dysfunction at 30 days | 30 days |
Countries
Belgium
Outcome results
None listed